Abstract: Provided herein are methods for treating cancer and for selecting a cancer treatment based on the expression of Stag2/3 proteins and/or the presence of mutations in the genes encoding Stag2/3 proteins.

Abstract: The present invention discloses a nano-armored single cell product, comprising a liposome and probiotics encapsulated by the liposome, wherein the probiotics are fermented to produce gamma-aminobutyric acid (GABA) that alleviates the activation of an inflammatory response in substantia nigra inducedin a MPTP induced PD model, thus mitigating an inflammatory injury to dopaminergic neurons in substantia nigra and having a neuroprotective effect; encapsulation of the probiotics by the liposome can protect the probiotics from strong acids and digestive enzymes in gastric acid.

Abstract: The present invention discloses a nano-armored single cell product, comprising a liposome and probiotics encapsulated by the liposome, wherein the probiotics are fermented to produce gamma-aminobutyric acid (GABA) that alleviates the activation of an inflammatory response in substantia nigra inducedin a MPTP induced PD model, thus mitigating an inflammatory injury to dopaminergic neurons in substantia nigra and having a neuroprotective effect; encapsulation of the probiotics by the liposome can protect the probiotics from strong acids and digestive enzymes in gastric acid.

Abstract: A method for non-enzymatic 3D culture and amplification of mesenchymal stem cells (MSCs) includes the followings steps: preparing PLGA porous microspheres; preparing a PLGA-PEG-PLGA thermosensitive coating microcarrier; culturing and amplifying MSCs; and performing non-enzymatic separation of MSCs, including reducing a culture temperature to below a critical phase transition temperature, and centrifuging a culture medium to collect stem cells. The present invention adopts the method for non-enzymatic 3D culture and amplification of MSCs, wherein the PLGA porous microspheres are used as a cell culture microcarrier scaffold and the thermosensitive hydrogel PLGA-PEG-PLGA is coated on surfaces of such microspheres, without needing additional enzymolysis process, thus efficiently amplifying the stem cells.

Abstract: Embodiments provide a seat connecting device with an adjustable backrest, belonging to the technical field of swivel chairs. In the embodiments, the seat connecting device includes a seat back tightness control assembly including a control handle, a universal joint, a transmission rod, a first bevel gear, a second bevel gear, a lifting part, a mounting seat of the lifting part, and a tightness adjust rod.

Abstract: An mRNA vaccine microneedle product includes a backing and a mRNA vaccine solution-containing microneedle array attached to a side of the backing, wherein the mRNA solution-containing microneedle array includes several microneedles, and each microneedle contains a matrix and mRNA loaded in the matrix. The present invention adopts the mRNA vaccine microneedle product as well as a preparation method and an application thereof, and such microneedle product can realize a rapid humoral immunity after being administered to the skins of animal bodies (especially human bodies), which solves the problems of traditional vaccination, such as muscular pain and multiple injections.

Abstract: An inactivated virus vaccine microneedle product includes a backing and an inactivated virus-containing microneedle array attached to a side of the backing, wherein the inactivated virus-containing microneedle array includes a plurality of microneedles, and each microneedle contains a matrix and an inactivated virus loaded in the matrix. The present invention adopts the inactivated virus vaccine microneedle product as well as a preparation method and an application thereof, and such microneedle product realizes efficient transdermal absorption of a vaccine by loading an inactivated virus in the microneedle product after being administered to the skin, and a long-acting stable release of a vaccine is achieved, which solves the problems of traditional vaccination, such as muscular pain and multiple injections.

Abstract: A recombinant subunit vaccine microneedle product includes a backing and a recombinant subunit lung-associated virus vaccine solution-containing microneedle array attached to a side of the backing, wherein the recombinant subunit lung-associated virus vaccine solution-containing microneedle array includes a plurality of microneedles, wherein each microneedle contains a matrix and a recombinant subunit loaded in the matrix. The present invention adopts the recombinant subunit vaccine microneedle product as well as a preparation method and an application thereof, wherein such microneedle product can realize a rapid humoral immunity after being administered to the skins of animal bodies (especially human bodies), which solves the problems of traditional lung-associated virus vaccine injection, such as muscular pain and multiple injections.

Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula: Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Abstract: An exosome hydrogel for treating severe respiratory diseases is provided and includes a temperature-sensitive hydrogel and an exosome; wherein the temperature-sensitive hydrogel is PLGA-PEG-PLGA. According to the present invention, PLGA-PEG-PLGA generates a hydrogel exosome through a phase transition at a body temperature, and the hydrogel stays in lungs for a longer time than common exosomes, thereby making the exosome remain at an infection site and producing a better therapeutic effect. The exosome hydrogel features high safety, is suitable for promotion, and has good potential in medical treatment.

Abstract: The method of preparing polyethyleneimine-lipid nanoparticles (PEI-LNPs) for transfecting stem cells includes the following steps: S1, adding anhydride to a PEI solution to produce polycarboxylic acid; S2, dissolving the PEI-LNPs from S1, together with DPPC, DPPG, DPPE-PEG-COOH and cholesterol in chloroform, dissolving cGAMP in a water and then adding to such chloroform solution, and performing vacuum evaporation to remove the chloroform; S3, adding PBS for hydration, and performing ultrasonication to obtain liposomes; and S4, adding EDC/NHS to the liposome solution obtained for reaction for 15 min, then adding mRNA, and stirring the mixed solution to obtain a bionic virus nanovaccine. The prepared PEI-LNPs are used for delivering an mRNA vaccine and transfecting stem cells, wherein through a lipid PEI derivative library synthesized based on short-branched PEI with a variable length and hydrophobic tail substitution ratio, short-branched PEI can form a stable complex with the mRNA vaccine.

Abstract: A method for preparing an atomizing SARS-CoV-2 nanovaccine includes the followings steps: mimicking a structure of SARS-COV-2 with receptor binding domains (RBDs) of SARS-COV-2, by taking Poly(I:C) mimicking viral genetic materials as an immunoadjuvant, and electronegative liposomes that enter pulmonary macrophages efficiently as a viral capsid structure; adding a catalyst and an RBD antigen protein to a liposome solution, linking the antigen protein to a liposome surface, and obtaining a bionic virus nanovaccine after purification and freeze-drying treatment. Compared with conventional intramuscular and subcutaneous inoculation, the SARS-CoV-2 vaccine of the present invention features strong mucosal protection effect, high safety, extensive application, and excellent potential.

Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

Abstract: The disclosure describes chiral P(V)-based reagents and their uses for the modular, scalable, and stereospecific synthesis of chiral phosphines, phosphine oxides and particular oligonucleotides.

Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

Abstract: The present invention discloses an anti-hair loss and hair growth integrated core-shell microneedle patch, comprising a backing and a core-shell microneedle array attached to one side of the backing, the core-shell microneedle array comprises a plurality of microneedles arranged on the backing to form an array, each microneedle comprises a shell substrate material and an internal core, and the shell substrate material is loaded with nano-enzyme for removing excessive active oxygen.

Abstract: The present invention discloses a nano-armored single cell product, comprising a liposome and probiotics encapsulated by the liposome, wherein the probiotics are fermented to produce gamma-aminobutyric acid (GABA) that alleviates the activation of an inflammatory response in substantia nigra inducedin a MPTP induced PD model, thus mitigating an inflammatory injury to dopaminergic neurons in substantia nigra and having a neuroprotective effect; encapsulation of the probiotics by the liposome can protect the probiotics from strong acids and digestive enzymes in gastric acid.